Quantification of Abs toward a single epitope is critical to understanding immunobiological processes. In autoimmunity, the prognostic value of the serological profiles of patients draws much attention, but the detection of Abs toward a single epitope is not well controlled. Particularly, the rheumatoid arthritis (RA)-specific anti-citrullinated protein/peptide Abs (ACPA) are specific to a two-atom change on arginyl residues and are considered a heterogeneous family of Abs. As a model, we studied ACPA to decipher how peptide features used as immunosorbent impact Ab detection. We synthesized 30 peptides encompassing immunodominant epitopes of citrullinated fibrin differing by their length and biotin location and tested them using ELISA with 120 sera from RA and non-RA rheumatic disease controls, generating over 3000 experimental measurements. We showed that minor molecular changes in peptide chemical structure had dramatic consequences. Even when peptides exhibited the same epitope, measured Ab titers were extremely variable, and patients' seropositivity was discordant in up to 50% of cases. The distance between epitope and biotin was the most critical parameter for efficient Ab detection irrespective of biotin position or peptide length. Finally, we identified a 15-mer peptide bearing a single citrullinated epitope detecting almost all ACPA-positive sera, thus revealing a high degree of homogeneity in RA autoimmune response. This integrative analysis deciphers the dramatic impact of the molecular design of peptide-based technologies for epitope-specific Ab quantification. It provides a model for assay development and highlights that the studies using such technologies can give a wrong perception of biological processes and therefore that medical use of data must be cautious.

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1800330DOI Listing

Publication Analysis

Top Keywords

anti-citrullinated protein/peptide
8
abs single
8
single epitope
8
epitope
5
seropositivity antibody
4
antibody profiling
4
profiling patients
4
patients dramatically
4
dramatically impacted
4
impacted features
4

Similar Publications

Background: 20-40% of patients with rheumatoid arthritis (RA) present an extra-articular manifestation (EAM) and 1-20% a severe EAM, with an increased risk of death (> 2 times). The associated lesions are: 27.5% rheumatoid nodules, and 0.

View Article and Find Full Text PDF

Introduction Anti-citrullinated protein/peptide antibodies (ACPA) are crucial for the diagnosis and prognosis of rheumatoid arthritis (RA) and are associated with class II HLA-DRB1 alleles. The study's goal was to determine how DRB1 alleles and hematological and biochemical parameters affect ACPA production in RA patients from Sudan. Methods The study analyzed the hematological and biochemical parameters and the frequency of HLA-DRB1 alleles in 120 RA patients and 100 controls.

View Article and Find Full Text PDF

Aim: To clarify the prognosis and prognostic factors for lung cancer in patients with rheumatoid arthritis (RA).

Methods: In this retrospective longitudinal study, we investigated the medical records of patients with RA among 1422 patients diagnosed with lung cancer and registered in a hospital-based cancer registry between January 2013 and May 2022. The Kaplan-Meier method and Cox proportional hazards model were used to analyze survival and identify predictive factors.

View Article and Find Full Text PDF

Current classification criteria for rheumatoid arthritis (RA) encompass clinical and immunological items and are capable of correctly identifying the majority of symptomatic RA patients. The presence of positive rheumatoid factor (RF) and/or and anti-cyclic citrullinated protein/peptide antibodies (ACPA) gaining increasing importance according to their serological titer eases the recognition of RA, yet the debate is open on whether this scoring system ought to be optimized by hierarchizing ACPA or the combination of ACPA and RF over single positivity, prioritizing specificity over sensitivity. The risk of misdiagnosis and misclassification are often entangled, yet they are not the same.

View Article and Find Full Text PDF
Article Synopsis
  • A study investigated the real-world effectiveness and safety of Janus kinase inhibitors (JAKis) in older patients with rheumatoid arthritis (RA), focusing on those aged 65 and above.
  • 133 patients were divided into "very elderly" (≥75 years) and "elderly" (65-74 years) groups to compare drug retention rates.
  • Results showed similar discontinuation rates due to adverse events and effectiveness in both age groups, with factors like chronic lung disease impacting these rates, and lower retention in patients receiving the approved dose of JAKis compared to those on reduced doses.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!